Aixcrypto Holdings, Inc. · NASDAQ:AIXC
Aixcrypto — Qualigen Therapeutics — BIO Investor Forum (October 2023)
21 slides from Aixcrypto's conference presentation, Oct 17, 2023
Slide 1: Corporate Presentation, BIO Investor Forum
qualigen THERAPEUTICS WM Driven to Deliver Corporate Presenta BIO Investor Forum
Slide 2: Forward-Looking Statement
Forward-Looking Statement qualiger This presentation contains statements about our future expectations, plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, These statements include those re
Slide 3: Investment Highlights
Investment Highlights qualigen * Clinical-stage therapeutic company developing platform treatments for rare adult and pediatric cancers with potential for Orphan Drug Designation * Oncology-focused therapeutic pipeline: * QN-302, G4-selective transcription inhibitor for potential treatment of G4-tar
Slide 4: Therapeutic Pipeline
qualigen Therapeutic Pipeline G4-Targeted Tumors QN-302 (PDAC’, prostate, sarcomas, GIST’) Advanced Solid Tumors UNIVERSITY Foun’ (RAS-ctiven) of LOUISVILLE, Nucleolin-Expressing QN-2477 Malignancies oflOUNHLE, (INBC’, AML’) tActively seeking to outlicense “PDAC= Pancreatic Ductal Adenocarcinoma, sr
Slide 5: Anticipated Milestones
+ Readout of additional data on in vivo model(s) + Select partner for G4 biomarker development * Initiate activation of first Phase 1a clinical trial site * Enroll first patient in Phase 1a dose escalation clinical study Pa AS + Present data at major scientific conference? * Identification of in viv
Slide 6: QN-302: G4-Selective Transcription Inhibitor
qualigen THERAPEUTICS WM Driven to Deliver ( QN-302: G4-Selective Transcription Inhibitor
Slide 7: Targeting G4s to Inhibit Cancer Replication
Targeting GAs to Inhibit Cancer Replication Qualigen licensed G4°-Selective Transcription Inhibitors from UCL in January 2022, including lead compound QN-302 Gés are overrepresented in many oncogenes; their prevalence is significantly greater in cancerous vs. normal cells QN-302 has stabilized G4 co
Slide 8: QN-302: Pancreatic Cancer
QN-302: Pancreatic Cancer qualigen * Pancreatic cancer is the 3° deadliest cancer in the US! * Five-year survival rate of only 11.5%! * 1-in-4 die within the first month after diagnosis? * Annual pancreatic cancer therapeutics market projected to grow (CAGR~7.54%) to $3.73B by 20279 * QN-302 has sho
Slide 9: QN-302: Significantly Inhibited Tumor Growth
Tumor Volume (Percent of starting volume) QN-302: Significantly Inhibited Tumor Growth Xenograft Data in MIA-PACA2 Pancreatic Cancer Mouse Model Vehicle control BIW* Dosing stopped QN-302 Img/kg BIW qualigen QN-302 produced tumor growth arrest and tumor regression in vivo MIA-PACA2 xenograft mouse m
Slide 10: QN-302: PDAC PDX Tumor Characteristics
QN-302: PDAC PDX Tumor Characteristics PDAC PDX mouse xenografts with QN-302 at the “standard” dose qualigen Tumor Volumes for Model #1 Tumor Volumes for Model #2 PRE NEceaONAET ci emeltahine shg0t Vee mana —4-03Gemcatne ‘00 3 200 E sm 5 so 3 s0 of 0 10 20 7 3 2B 23 33 4B Day Day ges “Cuble Milimete
Slide 11: QN-302: Potent Growth Inhibitor in Prostate Xenografts
QN-302 showed potent growth inhibition in some prostate cancer lines, especially PC-3 *-Vehicle eAbiateron 00 mg/kg @D a 02 Img/kg B/W 800 Prostate cancer: QN-302: Potent Growth Inhibitor in Prostate Xenografts qualigen e fines QN-302 | Abiraterone _ Enzalutamide E PC 3 4820 5350 2 | Duras 32 N/A N/
Slide 12: QN-302: Proposed Phase 1a Clinical Study
QN-302: Proposed Phase 1a Clinical Study Primary Objective: Safety, Tolerability, Recommended Phase 2 Dose (RP2D) Study Design: Open-label, multicenter, dose- escalation and expansion, safety, pharmacodynamics, pharmacokinetics Dosing: Single agent, intravenously at four dose levels (3+3 design) Nas
Slide 13: Pan-RAS: Small Molecule Platform
qualigen THERAPEUTICS WM Driven to Deliver Pan-RAS: Small Molecule Platform
Slide 14: RAS: Key Driver for Advanced Solid Tumors
RAS: Key Driver for Advanced Solid Tumors * RAS is the most common cancer oncogene, present in more than 30% of all cancers* * Activates mutations in one of the three human RAS gene isoforms (KRAS, HRAS or NRAS) * Acts asa “hub” that activates multiple effectors; blocking any single pathway can be i
Slide 15: RAS Mutant Prevalence By Cancer Type
G120 Gi2v Other Gree Gis0 AMP Grr G12A Multiple Ee and NE 0 «€& a RAS Mutant Prevalence By Cancer Type > 3 qualigen dh Taal TR PORE uA = im s__| [cen PR) he 25) | 0-5] [If +525 0%] [ff 5257 @0%)] [275020] |[ 7900] | aoe 0.45) p29 FRE 02%) | 5.05 6.0%) {ff .000,¢2%)| || ex 3%] || 1900074] || 170 00%)
Slide 16: Potent Antitumor Activity in Mouse Xenograft
Potent Antitumor Activity in Mouse Xenograft MiaPaca-2 Mouse Xenogratt 4000 = 800 E soy sooner ry © cartier = | waxctow & “a ANG510 (Somalia) s* z ry te F3-8-60 (100mg/kg) En — ie < Zz 5 Dose regimen: 4. 200 _# qd, 21 days a . ° 3 oMso o 5 mt Os Days MiaPace-2 (K12C) pancreatic adenocarcinoma cells
Slide 17: Enhanced Effects of Immune Checkpoint Therapy in Syngeneic Tumor Graft
Enhanced Effects of Immune Checkpoint Therapy in Syngeneic Tumor Graft qualigen KPC Mouse KPC-Derived Xenograft* ° |= € 80 ns c= S : * Re -tees Dose regimen: © 4 = T mg/kg ip i= Pr0.018 2d, 28 days 3S 2 $ S = 5 2 *KPC cells = RAS*/p53* murine cell line from a — _ transgenic mouse pancreatic adenocar
Slide 18: Synergistic with AMG-510 and MRTX1133 In Vitro
qualigen ynergistic with AMG-510 and MRTX1133 In Vit Soft agar assay indicating that the combination of our pan-RAS inhibitors and established G12C (AMG510) and G12D (MRTX1133) RAS inhibitors synergize to block anchorage-independent growth of pancreatic cancer cells. Co-operation between RAS-F serie
Slide 19: In Summary
In Summary qualigen Nasdaq: QLGN Clinical-stage therapeutic company developing platform treatments for rare adult and pediatric cancers with potential for Orphan Drug Designation * QN-302, G4-selective transcription inhibitor for potential treatment of G4-targeted tumors * Pan-RAS platform for poten
Slide 20: Leadership Team
Leadership Team qualigen Michael S. Poirier Chief Executive Officer, Chairman Founded Qualigen in Previous operations, Tariq Arshad, MD, MBA SVP, Chief Medical Officer Pasteur and Ashirus Technol Officer in the United Stat tothe leet PL sti Christopher Lotz Drew Hertig, MBA, CLP Veal VP, Chief Finan
Slide 21: Slide 21
Qualigen Therapeutics — BIO Investor Forum (October 2023) on 6ix